Fractures after antiretroviral initiation

AIDS

Volumn 26, Issue 17, 2012, Pages 2175-2184

  Yin, Michael T ^a   Kendall, Michelle A ^b   Wu, Xingye ^b   Tassiopoulos, Katherine ^b   Hochberg, Marc ^c   Huang, Jeannie S ^d   Glesby, Marshall J ^e   Bolivar, Hector ^f   McComsey, Grace A ^g  

^a NewYork Presbyterian Hospital   (United States)

^b CENTER FOR BIOSTATISTICS IN AIDS RESEARCH   (United States)

^c UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^e WEILL CORNELL MEDICAL COLLEGE   (United States)

^f UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^g CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

antiretroviral initiation; bone loss; fracture; fracture incidence; HIV

Indexed keywords

ABACAVIR; EFAVIRENZ; GLUCOCORTICOID; LAMIVUDINE; RITONAVIR; STAVUDINE; TENOFOVIR; ZIDOVUDINE;

ADULT; ARTICLE; BONE DENSITY; DRUG EXPOSURE; DRUG USE; FEMALE; FRACTURE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; MAJOR CLINICAL STUDY; MALE; PREDICTOR VARIABLE; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; SMOKING;

ACCIDENTAL FALLS; ACQUIRED IMMUNODEFICIENCY SYNDROME; ADULT; ANTI-HIV AGENTS; BODY MASS INDEX; BONE DENSITY; CD4 LYMPHOCYTE COUNT; FEMALE; FOLLOW-UP STUDIES; FRACTURES, BONE; GLUCOCORTICOIDS; HIV SEROPOSITIVITY; HUMANS; INCIDENCE; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; QUESTIONNAIRES; RETROSPECTIVE STUDIES; SMOKING; TIME FACTORS;

EID: 84869496680     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e328359a8ca     Document Type: Article

References (34)

1. Brown TT, Qaqish RB. Antiretroviral therapy and the prevalence of osteopenia and osteoporosis: a meta-analytic review. AIDS 2006; 20:2165-2174.
2. Brown TT, McComsey GA, King MS, Qaqish RB, Bernstein BM, da Silva BA. Loss of bone mineral density after antiretroviral therapy initiation, independent of antiretroviral regimen. J Acquir Immune Defic Syndr 2009; 51:554-561.
3. Cassetti I, Madruga JV, Suleiman JM, Etzel A, Zhong L, Cheng AK, et al. The safety and efficacy of tenofovir DF in combination with lamivudine and efavirenz through 6 years in antiretroviral- naive HIV-1-infected patients. HIV Clin Trials 2007; 8:164-172.
4. Duviver C, Kolta S, Assoumou L, Gohosn J, Rozenberg S, Murphy R, et al. First-line PI-containing regimens enhance decreased bone mineral density greater than NNRTI-containing regimen in HIV-1 infected patients: A substudy of the HIPPOCAMPE-ANRS 121 Trial. Proceedings of the 15th Conference on Retroviruses and Opportunistic Infections; February 3-6, 2008; Boston, Massachusetts.
5. Grund B, Peng G, Gibert CL, Hoy JF, Isaksson RL, Shlay JC, et al. Continuous antiretroviral therapy decreases bone mineral density. AIDS 2009; 23:1519-1529.
6. Rivas P, Gorgolas M, Garcia-Delgado R, Diaz-Curiel M, Goyenechea A, Fernandez-Guerrero ML. Evolution of bone mineral density in AIDS patients on treatment with zidovudine/lamivudine plus abacavir or lopinavir/ritonavir. HIV Med 2008; 9:89-95.
7. Tebas P, Umbleja T, dube MP, Parker RA, Mulligan K, Roubenoff R, et al. Initiation of ART is associated with bone loss independent of the three specific ART regimens: Results of ACTG A5005 s. Proceedings of the 14th Conference on Retroviruses and Opportunistic Infections; February 25-28, 2007; Los Angeles, USA.
8. McComsey GA, Kitch D, Daar ES, Tierney C, Jahed NC, Tebas P, et al. Bone mineral density and fractures in antiretroviral-naive persons randomized to receive abacavir-lamivudine or tenofovir disoproxil fumarate-emtricitabine along with efavirenz or atazanavir-ritonavir: AIDS Clinical Trials Group A5224 s, a Substudy of ACTG A5202. J Infect Dis 2011; 203:1791-1801.
9. Dolan SE, Kanter JR, Grinspoon S. Longitudinal analysis of bone density in human immunodeficiency virus-infected women. J Clin Endocrinol Metab 2006; 91:2938-2945.
10. Mondy K, Yarasheski K, Powderly WG, Whyte M, Claxton S, DeMarco D, et al. Longitudinal evolution of bone mineral density and bone markers in human immunodeficiency virus-infected individuals. Clin Infect Dis 2003; 36:482- 490.
11. Yin MT, Lu D, Cremers S, Tien PC, Cohen MH, Shi Q, et al. Short-term bone loss in HIV-infected premenopausal women. J Acquir Immune Defic Syndr 2010; 53:202-208.
12. Guaraldi G, Orlando G, Zona S, Menozzi M, Carli F, Garlassi E, et al. Premature age-related comorbidities among HIV-infected persons compared with the general population. Clin Infect Dis 2011; 53:1120-1126.
13. Triant VA, Brown TT, Lee H, Grinspoon SK. Fracture prevalence among human immunodeficiency virus (HIV)-infected versus non-HIV-infected patients in a large U. healthcare system. J Clin Endocrinol Metab 2008; 93:3499-3504.
14. Yin MT, Shi Q, Hoover DR, Anastos K, Sharma A, Young M, et al. Fracture incidence in HIV-infected women: results from the Women's Interagency HIV Study. AIDS 2010; 24:2679- 2686.
15. Womack JA, Goulet JL, Gibert C, Brandt C, Chang CC, Gulanski B, et al. Increased risk of fragility fractures among HIV infected compared to uninfected male veterans. PloS One 2011; 6:e17217.
16. Young B, Dao CN, Buchacz K, Baker R, Brooks JT. Increased rates of bone fracture among HIV-infected persons in the HIV Outpatient Study (HOPS) compared with the US general population, 2000-2006. Clin Infect Dis 2011; 52:1061-1068.
17. Hansen AB, Gerstoft J, Kronborg G, Larsen CS, Pedersen C, Pedersen G, et al. Incidence of low and high-energy fractures in persons with and without HIV-infection: a Danish populationbased cohort study. AIDS 2012; 26:285-293.
18. Bedimo R, Maalouf NM, Zhang S, Drechsler H, Tebas P. Osteoporotic fracture risk associated with cumulative exposure to tenofovir and other antiretroviral agents. AIDS 2012; 26:825-831.
19. Yong MK, Elliott JH, Woolley IJ, Hoy JF. Low CD4 count is associated with an increased risk of fragility fracture in HIVinfected patients. J Acquir Immune Defic Syndr 2011; 57:205- 210.
20. Collin F, Duval X, Le Moing V, Piroth L, Al Kaied F, Massip P, et al. Ten-year incidence and risk factors of bone fractures in a cohort of treated HIV1-infected adults. AIDS 2009; 23:1021- 1024.
21. Hasse B, Ledergerber B, Furrer H, Battegay M, Hirschel B, Cavassini M, et al. Morbidity and aging in HIV-infected persons: the Swiss HIV cohort study. Clin Infect Dis 2011; 53:1130-1139.
22. Young B, Dao CN, Buchacz K, Baker R, Brooks JT. Increased rates of bone fracture among HIV-infected persons in the HIV Outpatient Study (HOPS) compared with the US general population, 2000-2006. Clin Infect Dis 2011; 52:1061- 1068.
23. Mundy LM, Youk AO, McComsey GA, Bowlin SJ. Overall benefit of antiretroviral treatment on the risk of fracture in HIV: nested casecontrol analysis in a health-insured population. AIDS 2012; 26:1073-1082.
24. Bosch RJ, Bennett K, Collier AC, Zackin R, Benson CA. Pretreatment factors associated with 3-year (144-week) virologic and immunologic responses to potent antiretroviral therapy. J Acquir Immune Defic Syndr 2007; 44:268- 277.
25. Smurzynski M, Collier AC, Koletar SL, Bosch RJ, Wu K, Bastow B, et al. AIDS clinical trials group longitudinal linked randomized trials (ALLRT): rationale, design,;1; and baseline characteristics. HIV Clin Trials 2008; 9:269-282.
26. Burnham KP, Anderson DR. Model selection and multimodel inference: a practical information-theoretic approach. 2nd ed. New York: Springer-Verlag; 2002.
27. Melton LJ 3rd, Crowson CS, O'Fallon WM. Fracture incidence in Olmsted County, Minnesota: comparison of urban with rural rates and changes in urban rates over time. Osteoporos Int 1999; 9:29-37.
28. Schiefke I, Fach A, Wiedmann M, Aretin AV, Schenker E, Borte G, et al. Reduced bone mineral density and altered bone turnover markers in patients with noncirrhotic chronic hepatitis B or C infection. World J Gastroenterol 2005; 11:1843- 1847.
29. Collier J. Bone disorders in chronic liver disease. Hepatology 2007; 46:1271-1278.
30. Nanda KS, Ryan EJ, Murray BF, Brady JJ, McKenna MJ, Nolan N, et al. Effect of chronic hepatitis C virus infection on bone disease in postmenopausal women. Clin Gastroenterol Hepatol 2009; 7:894-899.
31. Lo Re V 3rd, Guaraldi G, Leonard MB, Localio AR, Lin J, Orlando G, et al. Viral hepatitis is associated with reduced bone mineral density in HIV-infected women but not men. AIDS 2009; 23:2191-2198.
32. Lo Re V, 3rd, Volk J, Newcomb CW, Yang YX, Freeman CP, Hennessy S, et al. Risk of hip fracture associated with hepatitis C virus infection and hepatitis C/HIV coinfection. Hepatology 2012.
33. van Staa TP, Leufkens HG, Cooper C. The epidemiology of corticosteroid-induced osteoporosis: a meta-analysis. Osteoporos Int 2002; 13:777-787.
34. National Osteoporosis Foundation. Clinician's guide to prevention and treatment of osteoporosis. Washington, DC: National Osteoporosis Foundation; 2010.